Key result
Blood-based biomarkers show promise over invasive testing for diagnosing CMD but lack extensive validation.
Why the study?
Can blood-based biomarkers be used for the diagnosis and prognostication of coronary microvascular disease?
Can blood-based biomarkers be used for the diagnosis and prognostication of coronary microvascular disease?
While various blood-based biomarkers show potential for diagnosing and managing coronary microvascular disease, none have been extensively validated for routine clinical use.
No takes yet. Share an insight, caveat, or question.
Does not support routine clinical use of blood-based biomarkers for coronary microvascular disease; leaves open the need for prospective validation.
Hung et al. (2016) conducted a review in Coronary microvascular disease. Blood-based biomarkers vs. Invasive procedures (coronary reactivity testing) was evaluated. Blood-based biomarkers offer potential advantages over invasive testing for diagnosing coronary microvascular disease, but none have yet been extensively validated.